Differences of blood cells, lymphocyte subsets and cytokines in COVID-19 patients with different clinical stages: a network meta-analysis

Wu Yan,Danrong Chen,Francis Manyori Bigambo,Hongcheng Wei,Xu Wang,Yankai Xia
DOI: https://doi.org/10.1186/s12879-021-05847-9
IF: 3.7
2021-02-08
BMC Infectious Diseases
Abstract:Abstract Background Due to the rapid spread of coronavirus disease 2019 (COVID-19) worldwide, it is necessary to ascertain essential immune inflammatory parameters that describe the severity of the disease and provide guidance for treatment. We performed network meta-analyses to determine differences in blood cells, lymphocyte subsets, and cytokines in COVID-19 patients with different clinical stages. Methods Databases were systematically searched to May 2, 2020, and updated on June 1, 2020. Network meta-analyses were conducted via Stata 15.0, and the mean difference (MD) and its 95% CI were used as the effect values of the pooled analysis. Results Seventy-one studies were included involving 8647 COVID-19 patients, White blood cell (WBC), neutrophil (NEUT), IL-6, and IL-10 counts increased significantly with worsening of the COVID-19, while lymphocyte (LYM) counts decreased. The levels of platelet (PLT), CD3 + , CD4 + , CD8 + , and CD19 + cells in severe and critical patients were significantly lower than those in mild patients. IL-1β count was significantly elevated in critical patients. Conclusions Immune suppression and inflammatory injury play crucial roles in the progression of COVID-19, and the identification of susceptible cells and cytokines provide guidance for the early and accurate treatment of COVID-19 patients.
infectious diseases
What problem does this paper attempt to address?